Videos

Brett King, MD, PhD, reviews how the drug class has altered the state of chronic skin disease management in this year alone.

Why patience is key following the major FDA decision earlier this year.

In the QUSAR study, 80% of patients treated with guselkumab achieved a clinical response.

A review of the development of complement inhibitors and how the latest GATHER2 data support avacincaptad pegol for the treatment of geographic atrophy.

Dr. Demirjian explained suggested changes to how dialysis is conducted in hospital settings.

There are plans for a larger sized study testing zetomipzomib in patients with lupus nephritis.

With the population aging, there is a need for more home environmental treatment options for patients with kidney disease.

The study shows vitamin D levels do not necessarily forecast the risk of cardiovascular disease in patients with chronic kidney disease.

Females generally have a lower risk of cardiovascular disease compared to males.

After the announced recall of dry shampoo products by Unilever this month, dermatologists anticipate an uptick in patient concerns.

Lawrence Eichenfield, MD, discusses recent achievements in identifying and possibly preventing atopic dermatitis development in infants.

Welcome back to Crisis Point. A special episode focuses on the issue of insulin accessibility and affordability in the United States, with four experts in the diabetes arena weighing in on the topic.

A greater proportion of the upadacitinib 15 mg and upadacitinib 30 mg group achieved clinical remission based on the Crohn’s Disease Activity Index

Dupilumab represents the first ever approved treatment for EoE.

If approved by the FDA, RBX2660 would be the first approved live microbiota therapeutic for the treatment of recurrent CDI.

The COVID-19 pandemic has hurt the effort of colorectal cancer screenings.

With dupilumab already available and JAK inhibitors on the way, clinicians have a bevy of treatments designated for pediatric patients.

In consideration of emerging JAK inhibitor options, and the current prescribing availability of baricitinib.

Brett King, MD, PhD, explains the altered screening and care strategies for patients following baricitinib's approval.

Brett King, MD, PhD, discusses the newly available JAK inhibitor—the first systemic therapy approved for the hair-loss condition.

The JAK inhibitor received FDA approval for vitiligo this summer. Investigator now see it as a potent non-steroidal option for eczema.

Christopher Bunick, MD, discusses the future progress of acne management—including a potential mRNA vaccine current in development.

With a broadening array of drug options, involving patients in the care process may be a key to adherence and long-term success.

Christopher Bunick, MD, PhD, reviews the benefit of antibiotic resistance, blood-brain barrier penetration, and digestive distress with agents like sarecycline.

Peter Lio, MD, shares his strategy for advancing severely impacted patients from systemic therapy to either upadacitinib or abrocitinib.

Martha Gulati, MD, joins episode 2 to discuss the burden of gender disparity in cardiovascular research, screening and care.

Dr. Reid Robison, MD, MBA, described his research on clinical depression and the recent acceptance of psychedelic medicine.

Rebecca T. Brown, MD, MPH, describes contributing factors to older homeless adult mortality and future topics of interest in this field.